Pharmafit Provence
AUREOMYCINE EVANS 3 % Ointment Tube/15g

DB Pharma

AUREOMYCINE EVANS 3 % Ointment Tube/15g

CIP / EAN code: 3400934213281

Product information from VIDAL.

Read the product information
Back to the catalogue

Product information

Find indications, dosage and precautions in the sections below.

Automatic English translation of the French VIDAL document. Original numerical values and units are retained, including decimal commas.

VIDAL
Medicines
Update of 12/05/2025

AUREOMYCINE EVANS® 3 %
chlortetracycline


Forms and presentations

Ointment:  Tube of 15 g.


Composition

  per tube
Chlortetracycline hydrochloride 
450 mg
Excipients: liquid paraffin, lanolin (wool fat), petrolatum.
Excipient with known effect: wool fat (lanolin).

Indications

Skin infections due to staphylococcus and streptococcus:
  • Impetigo and impetiginized dermatoses:
    • by local treatment only in localized forms with a small number of lesions;
    • as adjunctive local treatment in association with appropriate systemic antibiotic therapy in the most extensive forms.
  • Disinfection of cutaneous-mucosal microbial reservoirs, in healthy carriers of staphylococci, and after staphylococcal infection, notably furunculosis.
Official recommendations concerning the appropriate use of antibacterial agents should be taken into account.

Dosage and administration

Dosage

2 or 3 applications per day.

The duration of treatment should not exceed 8 days because of the risk of selection of resistant organisms.


Contraindications

  • Hypersensitivity to chlortetracycline or to any of the excipients listed in section Composition in particular to wool fat (lanolin).
  • Breast infections, during breastfeeding, because of the risk of ingestion of the product by the newborn (see Fertility/Pregnancy/Breastfeeding).

Warnings and precautions


Warnings:
  • In case of streptococcal infection, systemic antibiotic therapy should be considered.
  • Cutaneous sensitization may compromise the subsequent systemic use of an antibiotic of the same class.
Precautions for use
  • Because of the risk of photosensitization, avoid exposure to solar or artificial UV radiation.
  • Risk of selection of resistant organisms with prolonged treatment.
  • This ointment form is not suitable for treating weeping, macerated lesions, skin folds or leg ulcers.
  • This medicine contains lanolin (wool fat) and may cause local skin reactions (for example: contact dermatitis).

Fertility, pregnancy and breastfeeding

Breastfeeding:

Do not use in cases of breast infections during breastfeeding, due to the risk of the newborn ingesting the product.


Adverse effects

  • Possibility of allergic contact eczema.
    Eczema lesions may spread to areas distant from the treated sites.
  • Risk of photosensitisation.
Reporting of suspected adverse reactions:

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continuous monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals should report any suspected adverse reaction via the national reporting system: National Agency for the Safety of Medicines and Health Products (ANSM) and the network of Regional Pharmacovigilance Centres. Website: https://signalement.social-sante.gouv.fr.


Overdose

No cases of overdose have been reported.


Pharmacodynamics

Pharmacotherapeutic class: Antibiotic therapy for topical use (D. Dermatology), ATC code: D06AA02.

Chlortetracycline is an antibiotic of the tetracycline family.

Spectrum of antibacterial activity:
Critical concentrations separate susceptible strains from strains of intermediate susceptibility, and the latter from resistant strains: S ≤ 4 mg/L and R > 8 mg/L.
The prevalence of acquired resistance can vary according to geography and time for certain species. It is therefore useful to have information on local resistance prevalence, especially for the treatment of severe infections. These data can only provide guidance on the probabilities of the susceptibility of a bacterial strain to this antibiotic.
When the variability of resistance prevalence in France is known for a bacterial species, the frequency of acquired resistance in France (> 10 %; extreme values) is indicated in parentheses.
Susceptible species:
  • Aerobic Gram-positive: bacillus, enterococci (40 - 80 %), staphylococcus methicillin-S, staphylococcus methicillin-R* (70 - 80 %), streptococcus A (20 %), streptococcus B (80 - 90 %), Streptococcus pneumoniae (20 - 40 %).
  • Aerobic Gram-negative: Branhamella catarrhalis, brucella, Escherichia coli (20 - 40 %), Haemophilus influenzae (10 %), klebsiella (10 - 30 %), Neisseria gonorrhoeae, pasteurella, Vibrio cholerae.
  • Anaerobes: Propionibacterium acnes.
  • Others: Borrelia burgdorferi, chlamydia, Coxiella burnetii, leptospira, Mycoplasma pneumoniae, rickettsia, Treponema pallidum, Ureaplasma urealyticum.
Resistant species:
  • Aerobic Gram-negative: acinetobacter, Proteus mirabilis, Proteus vulgaris, pseudomonas, serratia.
*  The frequency of resistance to methicillin is approximately 30 to 50 % of all staphylococci and is found mostly in hospital settings.


Storage conditions

Shelf life
3 years.

Store at a temperature below 25 °C.


HANDLING/DISPOSAL INSTRUCTIONS

No special requirements.


Prescription, supply and reimbursement

LIST I
Marketing authorisation (AMM) 3400934213281 (1974/97, SmPC rev 19.12.2023).
Not reimbursed by Social Security. Collect.

Marketing authorisation holder: SCA Pharma.


DB PHARMA Laboratories
1 bis, avenue du Cdt-Rivière
La Varenne-St-Hilaire
94210 Saint-Maur-des-Fossés
Tel: 01 48 83 25 14. Fax: 01 48 83 27 57
http://www.db-pharma.com

Source: VIDAL · Updated on 10/11/2026. This information does not replace advice from a healthcare professional.